Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1854 1
1986 1
1991 1
1992 1
1993 1
1995 1
1996 4
1997 9
1998 7
1999 4
2000 6
2001 10
2002 7
2003 8
2004 6
2005 10
2006 5
2007 8
2008 12
2009 9
2010 8
2011 6
2012 6
2013 7
2014 7
2015 9
2016 4
2017 3
2018 1
2019 2
2020 2
2021 2
2022 1
2023 1
2024 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Sterling TR, et al. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. N Engl J Med. 2011. PMID: 22150035 Free article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap.
Nahid P, Saukkonen J, Mac Kenzie WR, Johnson JL, Phillips PP, Andersen J, Bliven-Sizemore E, Belisle JT, Boom WH, Luetkemeyer A, Campbell TB, Eisenach KD, Hafner R, Lennox JL, Makhene M, Swindells S, Villarino ME, Weiner M, Benson C, Burman W; National Institutes of Health; Centers for Disease Control and Prevention. Nahid P, et al. Among authors: burman w. Am J Respir Crit Care Med. 2011 Oct 15;184(8):972-9. doi: 10.1164/rccm.201105-0827WS. Am J Respir Crit Care Med. 2011. PMID: 21737585 Free PMC article.
Drug-resistance mechanisms and tuberculosis drugs.
Köser CU, Javid B, Liddell K, Ellington MJ, Feuerriegel S, Niemann S, Brown NM, Burman WJ, Abubakar I, Ismail NA, Moore D, Peacock SJ, Török ME. Köser CU, et al. Among authors: burman wj. Lancet. 2015 Jan 24;385(9965):305-7. doi: 10.1016/S0140-6736(14)62450-8. Lancet. 2015. PMID: 25706840 Free PMC article. No abstract available.
Predictable excess hepatotoxicity in the SimpliciTB trial.
Burman W, Horsburgh CR, Johnston J. Burman W, et al. Lancet Infect Dis. 2024 Dec;24(12):e727. doi: 10.1016/S1473-3099(24)00598-X. Epub 2024 Oct 28. Lancet Infect Dis. 2024. PMID: 39481423 No abstract available.
171 results